Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12186260rdf:typepubmed:Citationlld:pubmed
pubmed-article:12186260lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C0021368lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C0022417lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C0079189lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C1261381lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C1546857lld:lifeskim
pubmed-article:12186260lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:12186260pubmed:issue7lld:pubmed
pubmed-article:12186260pubmed:dateCreated2002-8-20lld:pubmed
pubmed-article:12186260pubmed:abstractTextA predominance of T-helper 1 (Th1) activity and a lack of Th2 activity has been documented in the inflamed joints of patients with rheumatoid arthritis (RA). This imbalance is suggested to contribute to activation of, particularly, inflammatory macrophages and B-cells. Th2-mediated immunity, like atopy, is associated with amelioriated inflammation and joint damage in RA patients. Despite the potent anti-inflammatory capacities of two prominent Th2 cytokines in many experimental studies, clinical trials with either human IL-4 or IL-10 in RA patients did not lead to substantial disease suppression. Based on a thorough evaluation of the actions of IL-4 and IL-10 in these studies, it is hypothesized that disease suppression of RA may require the concerted action of suppressive Th2 cytokines or Th2 activity.lld:pubmed
pubmed-article:12186260pubmed:languageenglld:pubmed
pubmed-article:12186260pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12186260pubmed:citationSubsetIMlld:pubmed
pubmed-article:12186260pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12186260pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12186260pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12186260pubmed:statusMEDLINElld:pubmed
pubmed-article:12186260pubmed:monthJullld:pubmed
pubmed-article:12186260pubmed:issn1472-4472lld:pubmed
pubmed-article:12186260pubmed:authorpubmed-author:BijlsmaJohann...lld:pubmed
pubmed-article:12186260pubmed:authorpubmed-author:LafeberFloris...lld:pubmed
pubmed-article:12186260pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:12186260pubmed:issnTypePrintlld:pubmed
pubmed-article:12186260pubmed:volume3lld:pubmed
pubmed-article:12186260pubmed:ownerNLMlld:pubmed
pubmed-article:12186260pubmed:authorsCompleteYlld:pubmed
pubmed-article:12186260pubmed:pagination1011-6lld:pubmed
pubmed-article:12186260pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:meshHeadingpubmed-meshheading:12186260...lld:pubmed
pubmed-article:12186260pubmed:year2002lld:pubmed
pubmed-article:12186260pubmed:articleTitleSuppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines.lld:pubmed
pubmed-article:12186260pubmed:affiliationDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, The Netherlands. J.vanRoon@azu.nllld:pubmed
pubmed-article:12186260pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12186260pubmed:publicationTypeReviewlld:pubmed